Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome
- Conditions
- Urinary Incontinence
- Interventions
- Device: Neuro-Muscular Stimulators (NMS)
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Target Recruit Count
- 110
- Registration Number
- NCT03468465
- Locations
- 🇪🇸
Hospital Clínico Universtario Virgen de la Arrixaca, El Palmar, Murcia, Spain
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
- Conditions
- Overactive BladderParkinson Disease
- Interventions
- Behavioral: Pelvic floor muscle exercise-based behavioral therapy
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 77
- Registration Number
- NCT03149809
- Locations
- 🇺🇸
Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States
🇺🇸Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States
🇺🇸Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States
Study of ONO-8577 in Patients With Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 207
- Registration Number
- NCT03106623
- Locations
- 🇯🇵
Gunma Clinical Site 02, Maebashi, Gunma, Japan
🇯🇵Hyogo Clinical Site 02, Akashi, Hyogo, Japan
🇯🇵Gunma Clinical Site 01, Takasaki, Gunma, Japan
Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 36
- Registration Number
- NCT02940314
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
- Conditions
- Benign Prostate Hyperplasia
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 588
- Registration Number
- NCT02827578
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
- Conditions
- Overactive Bladder
- Interventions
- Drug: Placebo of Succinate of Solifenacin
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Center Eugene Marquis
- Target Recruit Count
- 4
- Registration Number
- NCT02805452
- Locations
- 🇫🇷
CH Bretagne Sud, Lorient, France
🇫🇷Clinique Pasteur Lanroze, Brest, France
🇫🇷CH Lyon Sud, Lyon, France
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
- Conditions
- Lower Urinary Tract SymptomsOveractive BladderBenign Prostatic Hyperplasia (BPH)
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Astellas Pharma Taiwan, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02715024
- Locations
- 🇨🇳
Site, Taipei, Taiwan
Reproducibility Study of OABSS and Its Response to Treatment
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT02667470
- Locations
- 🇹🇭
Site: 1, Bangkok, Thailand
EC905 Pharmacokinetic Profile Study
- Conditions
- HealthyPhase 1Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 46
- Registration Number
- NCT02634489
- Locations
- 🇳🇱
Site NL1, Zuidlaren, Drente, Netherlands
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- Target Recruit Count
- 28
- Registration Number
- NCT02549196
- Locations
- 🇺🇸
PMG Research, Winston-Salem, North Carolina, United States
🇺🇸Quantum Laboratories, Deerfield Beach, Florida, United States
🇺🇸Miami Jewish Health Systems, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.